Benzamides/administration & dosage; Graft vs Host Disease/drug therapy; Graft vs Host Disease/mortality; Piperazines/administration & dosage; Protein Kinase Inhibitors/administration & dosage; Pyrimidines/administration & dosage; Adult; Aged; Antineoplastic Agents, Hormonal/administration & dosage; Antineoplastic Agents, Hormonal/adverse effects; Autoantibodies/blood; Benzamides/adverse effects; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease/blood; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Lymphoproliferative Disorders; Male; Middle Aged; Monitoring, Physiologic/methods; Myeloproliferative Disorders/mortality; Myeloproliferative Disorders/therapy; Piperazines/adverse effects; Prednisolone/administration & dosage; Prednisolone/adverse effects; Prospective Studies; Protein Kinase Inhibitors/adverse effects; Pyrimidines/adverse effects; Receptors, Platelet-Derived Growth Factor/blood; Severity of Illness Index; Survival Rate; Time Factors